1. Generics Bulletin
  2. >>Legal & IP

Vanda Falls Again As Teva, FDA Win Judgment In ‘Unlawful’ Tasimelteon Approval Case

Originator Argued That Teva’s Hetlioz ANDA Improper Due To Braille Omission On Label

 
• By Dean Rudge

A month after Vanda failed to win a trade secrets case against the US FDA corresponding to generic approvals for its brands Hetlioz and Fanapt, the originator has again fallen, this time to the agency and Teva in the alleged unlawful approval of the Israeli firm’s generic Hetlioz product.

Hand push red Red Cross mark to choose cancellation item , Approve and reject business and document
(Shutterstock)

A US district court in Washington D.C. has ruled in favor of Teva in Vanda Pharmaceuticals’ bid for summary judgment arguing that the US Food and Drug Administration’s approval of Teva’s generic version of the originator’s Hetlioz (tasimelteon) was unlawful, marking another defeat for serial litigator Vanda.

Having joined the suit shortly after it was filed by Vanda against the FDA in 2023, Teva has seen its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

US Court Agrees To Throw Out Viatris Wegovy Infringement Case

 
• By Dean Rudge

Viatris’ Mylan has won a key patent case against Novo Nordisk over generic Wegovy, with a US federal district judge ruling Mylan’s label did not encourage use that infringed Novo’s method-of-treatment patent.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By Dean Rudge

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.

US Federal Circuit Clears Path for MSN to Market Entresto Generic

 
• By Dean Rudge

Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

More from Products

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By Dave Wallace

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.